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INTRODUCTION
Although surgery is potentially curative for colorectal can-
cer, about 50% of all newly diagnosed patients ultimately
develop a metastatic disease (1). Intravenous 5-fluorouracil
(FU) has been the mainstay of chemotherapy for metastatic
or recurrent colorectal cancer for many years. Prolonged infu-
sion of 5-FU in combination with the biomodulator leucov-
orin (LV) has an improved safety and efficacy profile when
compared with bolus 5-FU/LV (2, 3), although there is an
inconvenience and morbidity associated with long-term cen-
tral venous access. 
In 1990s, two additional agents, irinotecan and oxaliplatin,
were found to exhibit activity against metastatic colorectal
cancer. Infused 5-FU/LV in combination with oxaliplatin, a
third generation platinum analog, proved more effective than
5-FU/LV alone in the first- and second-line treatment of me-
tastatic colorectal cancer. As such, the addition of oxaliplatin
to 5-FU/LV therapy significantly increased the response rates
and time to disease progression (TTP) compared with 5-FU/
LV in the first-line treatment of colorectal cancer in three
randomized studies (4, 5) and as second-line therapy versus
5-FU/LV (6). Recently, a large cooperative group trial (N9741)
showed significant improvements in the response rate, TTP,
and overall survival (OS) with oxaliplatin plus infused 5-FU/
LV versus irinotecan plus bolus 5-FU/LV (7).
Among various combination regimens of oxaliplatin plus
5-FU/LV, the FOLFOX4 regimen (oxaliplatin 85 mg/m2,
LV 200 mg/m2, 5-FU 400 mg/m2 bolus, and 5-FU 600 mg/
m2 continuous infusion) is the most extensively studied oxali-
platin-containing regimen, with consistently high levels of
antitumor activity against advanced colorectal cancer in phase
III clinical trials (4). Yet, despite the increased efficacy asso-
ciated with the FOLFOX4 regimen, the continuous infusion
schedule of 5-FU remains inconvenient and requires frequent
hospitalization or central venous catheterization.
Accordingly, the present study evaluated the efficacy and
safety of outpatient-basis chemotherapy with oxaliplatin plus
5-FU/LV as the first-line treatment for patients with advanced
colorectal cancer.
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Outpatient-basis Chemotherapy of Oxaliplatin, 5-fluorouracil, and 
Leucovorin as First-line Treatment for Patients with Metastatic or
Recurrent Colorectal Cancer
The objectives of the present study were to evaluate the efficacy and safety of an
outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as the
first-line treatment for patients with advanced colorectal cancer. Forty-three histo-
logically confirmed patients with metastatic or recurrent colorectal cancer were en-
rolled. The chemotherapy consisted of oxaliplatin 85 mg/m
2 as a 2-hr infusion on
day 1, plus leucovorin 30 mg/m
2 over 10 min, followed by bolus 5-fluorouracil 400
mg/m
2 and an 8-hr infusion of 5-fluorouracil 600 mg/m
2 on days 1 and 2 (modified
FOLFOX4), all of which were administered on an outpatient basis every 2 weeks.
The median age was 58 yr (range 33-72 yr), and 25 (58.1%) patients had metastatic
diseases. Eventually, 39 patients were assessable for efficacy and all assessable
for toxicity. Four (9.3%) complete responses and 11 (25.6%) partial responses were
confirmed, giving an overall response rate of 34.9% (95% CI; 20.0-49.7%). The
median time to progression and median overall survival for all patients was 6.1 months
and 17.4 months, respectively. Grade 3/4 neutropenia occurred in 2 patients (4.7%)
and febrile neutropenia was observed in 1 patient (2.3%). Modified FOLFOX4, an
outpatient-basis regimen, was found to be well-tolerated and effective as the first-
line chemotherapy in patients with advanced colorectal cancer.
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MATERIALS AND METHODS
Patient eligibility
All patients enrolled in the present study had histologi-
cally confirmed metastatic or recurrent colorectal cancer. The
patients’ age ranged from 18 to 75, with a performance sta-
tus of 0 to 2 on the Eastern Cooperative Oncology Group
(ECOG) scale. Plus, adequate hematological (WBC count
≥4×109/L, platelet count ≥100×109/L, hemoglobin ≥9
g/dL), renal (serum creatinine ≤1.5 mg/dL and creatinine
clearance ≤50 mL/min), and hepatic (total bilirubin ≤2.0
mg/dL and serum transaminase level ≤3 times the upper
limit of the normal range) functions were also required. Pati-
ents who had received adjuvant chemotherapy completed 4
weeks before entry were eligible (8, 9). However, patients were
ineligible if they had previously received palliative chemother-
apy or radiation therapy. Patients with CNS metastases, sec-
ondary malignancies, or other severe medical illnesses were
also excluded. The institutional review board of the authors’
institution approved the protocol, and written informed con-
sent was obtained from all patients before enrollment.
Study treatment 
On day 1, oxaliplatin (85 mg/m2) was given as a 2-hr infu-
sion in 500 mL of a 5% dextrose solution. On days 1 and 2,
LV (30 mg/m2) was administered as a 10-min infusion imme-
diately followed by 5-FU (400 mg/m2/d) given as a 10-min
iv bolus, and 5-FU (600 mg/m2/d) as a continuous 8-hr infusion
with a light shield (Fig. 1). Treatment was repeated every 2
weeks. All patients received a 5-HT3 receptor antagonist as
a routine emesis prophylaxis. Treatment was continued until
disease progression, unacceptable toxic effects, or patient refusal.
Dose modification
The next course of treatment only began when neutrophil
count was ≥1.5×109/L, the platelet count was ≥75×109/
L, and any other treatment-related toxicities were less than
or equal to grade 1; otherwise, treatment was withheld for
up to 2 weeks. If adverse events did not improve to grade 0
or 1 after 3 weeks, the patients were excluded from the study.
Treatment was continued at the same dose if patients expe-
rienced grade 1 toxicities or other toxicities considered by
the investigator unlikely to become serious or life threaten-
ing (e.g. alopecia). For all other treatment-related adverse
events with a grade 2 intensity or higher, the dose modifica-
tion scheme described below was implemented. No dose
reduction was required after the first appearance of a grade
2 toxicity, although treatment was interrupted until the toxi-
city was resolved to grade 0 to 1. The doses of oxaliplatin and
5-FU were reduced by 25% in patients who experienced a
second occurrence of a given grade 2 non-hematologic toxi-
city or any grade 3 hematologic or non-hematologic toxicity. 
The dose of oxaliplatin was reduced by 25% in subsequent
cycles in the case of persistent (≥14 days) or temporary (7
to 14 days) painful paresthesia, or functional impairment. If
patients experienced a third occurrence of a given grade 2 non-
hematologic toxicity, a second occurrence of a given grade 3
hematologic or non-hematologic toxicity, or any grade 4 toxi-
city, both doses were reduced by 50%. The oxaliplatin and
5-FU were both discontinued if, despite a dose reduction, a
given toxicity occurred for a fourth time at grade 2, a third
time at grade 3, or a second time at grade 4. If adverse events
did not improve to grade 0 or 1 after 3 weeks, the patients
were excluded from the study.
Study parameters
A screening assessment, including a medical history, physical
examination, electrocardiogram (ECG), chest radiography, and
tumor assessment, was conducted within 2 weeks before start-
ing treatment. Further assessments conducted within 7 days
before starting treatment included vital signs, an ECOG per-
formance status, and laboratory tests. Complete blood counts
were performed weekly during the first cycle and every cycle
thereafter, and biochemical tests performed before each cycle.
The computed tomography (CT) of measurable lesions was
assessed as a baseline and repeated every 3 cycles. The tumor
responses were classified according to the response evaluation
criteria in solid tumors (RECIST) guidelines (10). Patients with
a complete response (CR) or partial response (PR) required a
confirmatory disease assessment at least 4 weeks later. Adverse
events were graded according to NCI-CTC version 3.0.
Statistical analysis
An optimal, two-stage Simon design (11) was used to deter-
mine the exact number of patients included in the current
trial. The hypotheses was that H0: P≤P0 (0.15) versus H1:
P≥P1 (0.35) with  =0.05, and  =0.10 (90% power). Allow-
ing for a follow-up loss rate of 10%, the total sample size
was 42 patients with a measurable disease. All enrolled patients
were included in the intention-to-treat analysis of efficacy.
The TTP and OS analyses were all estimated using the Ka-
plan-Meier method. The TTP was calculated from the initia-
tion of chemotherapy to the date of disease progression, and
OS was measured from the initiation of chemotherapy to the
date of the last follow-up or death. The statistical data were
obtained using an SPSS software package (SPSS 11.5 Inc.
Chicago, IL, U.S.A.).
RESULTS
Patient characteristics
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December 2003 to July 2005, a total of 43 biopsy-proven
patients were enrolled in the current study. The median age
was 58 yr (range, 33-72 yr), and there were 22 males and
21 females. The primary tumor location was the colon in 21
patients (49%) and the rectum in 22 patients (51%). Eigh-
teen patients (42%) received chemotherapy for recurred dis-
eases and 25 patients (58%) for metastatic diseases. The most
common metastatic site was the liver in 30 patients (70%).
Before chemotherapy, 40 patients (93%) received operative
therapy, which was curative in the case of 16 patients and
palliative in the other 24 cases. Fourteen patients (10 pati-
ents: 5-FU/LV, 4 patients: capecitabine) received adjuvant
chemotherapy after surgery. There was no significant differ-
ence in baseline characteristics between chemotherapy naive
group and adjuvant chemotherapy group.
Objective tumor response and survival
Thirty-nine of the original 43 patients were assessable for
response, with the remaining 4 being lost to follow-up or
patient refusal. All relevant data are reported using the inten-
tion-to-treat patient population. Four cases of CR and 11
cases of PR were confirmed, giving an overall response rate
of 34.9% (95% CI; 20.0-49.7%) (Table 2). The median dura-
tion of response in the 15 responding patients was 185 days
(range, 50-417 days). The median TTP for all patients was
6.1 months (95% CI; 3.3-8.9 months) with a median follow-
up duration of 9.4 months (95% CI; 0.3-25.3 months) (Fig.
1). In the case of progression, 2nd-line chemotherapy was
recorded for 20 patients, where 17 received FOLFIRI (irinote-
can 180 mg/m2, LV 30 mg/m2, 5-FU 400 mg/m2 bolus, and
5-FU 600 mg/m2 continuous infusion) and 3 received cape-
citabine (2,500 mg/m2). The median OS was 17.4 months
(95% CI; 10.9-23.8 months) with an estimated 1-yr survival
rate of 68.4% (95% CI; 60.0-76.8%) (Fig. 2). There was no
significant difference in the overall response rate, TTP, and
between chemotherapy naive group and adjuvant chemother-
apy group (data not shown).
Toxicities
A total of 284 cycles of chemotherapy were administered
to the 43 patients. The median number of cycles was 9, rang-
ing from 2 to 12 cycles. All patients were assessable for tox-
icities. The hematologic and non-hematologic toxicities that
occurred during the current study are summarized in Table
3. Grade 3/4 neutropenia occurred in 2 patients (4.7%), while
febrile neutropenia was observed in one patient (2.3%). All
cases were successfully treated with the granulocyte colony-
stimulating factor (G-CSF) and empirical antibiotics. Nau-
ECOG, Eastern Cooperative Oncology Group.
Characteristics Total (n=43)
Median age, yr (range) 58 (33-72)
Sex, - no. (%)
Male/female 22/21 (51/49)
ECOG performance status, no. (%)
0-1 41 (95)
2 2 (5)
Tumor location, no. (%)
Colon 21 (49)
Rectum 22 (51)
Pathology, no. (%)
Adenocarcinoma 42 (98)
Mucinous carcinoma 1 (2)
Disease status, no. (%)
Metastatic disease 25 (58)
Recurrent disease 18 (42)
Metastasis site, no. (%)
Liver 30 (70)
Peritoneum 9 (21)
Distant lymph node 8 (19)
Lung 5 (12)
Bone 3 (7)
Other sites 5 (12)
Previous operation, no. (%)
Total 40  (93)
Curative operation 16 (37)
Palliative operation 24 (56)
Adjuvant chemotherapy, no. (%)
Yes 14 (33)
Table 1. Patient characteristics
*95% CI, 20.0-49.7%; NA, not available.
No. of patients %
Objective response  15 34.9*
Complete response  4 9.3
Partial response  11 25.6
Stable disease  5 11.6
Progressive disease  19 44.2
NA 4 9.3
Table 2. Objective tumor response
Oxaliplatin 5FU infusion
85 mg/m
2 600 mg/m
2
0 hr 2 hr 10 hr
5-FU bolus 400 mg/m
2 for 10 min
Day 1
LV 30 mg/m
2 for 10 min
5FU infusion
600 mg/m
2
0 hr 8 hr
5-FU bolus 400 mg/m
2 for 10 min
Day 2
LV 30 mg/m
2 for 10 min
Fig. 1. The modified FOLFOX4 regimen. FU, fluorouracil; LV, leu-
covorin.
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sea was the most common non-hematologic toxicity. Grade
1/2 nausea was observed in 15 patients (34.9%), and only
one patient experienced grade 3 nausea. Nonetheless, no grade
IV non-hematologic toxicity was observed. Peripheral neu-
ropathy appeared in the form of transient cold exacerbated
paresthesia or dysesthesia, yet no grade 3/4 neuropathy was
observed. There was no case of death attributed to chemother-
apy-induced toxicity. The dose intensity of 5-FU and oxali-
platin was 94.5% and 93.4%, respectively.
DISCUSSION
In the current study, the modified FOLFOX4 regimen,
which can be administered on an outpatient basis, was shown
to have effective antitumor activity and a safe toxicity profile
in patients with metastatic or recurrent colorectal cancer. The
overall response rate (34.9%), median TTP (6.1 months), and
median OS (17.4 months) following treatment with the pre-
sent regimen were comparable with previous results reported
for the original FOLFOX4 regimen (3-5, 12, 13). For exam-
ple, Antre et al. (13) reported that the FOLFOX4 regimen
produced an overall response rate of 23.5%, median TTP of
5.1 months, and median overall survival of 11.1 months. Plus,
the recent phase II studies, which also adopted a low dose of
LV (modified FOLFOX4 regimen; oxaliplatin 85 mg/m2, LV
20 mg/m2, 5-FU 400 mg/m2 bolus, and 5-FU 600 mg/m2
continuous infusion) demonstrated a similar efficacy and toxi-
city to the original FOLFOX4 regimen (14-16). For patients
with metastastic colorectal cancer, where treatment is essen-
tially palliative, the protracted infusion times represent a sig-
nificant portion of the patient’s remaining life span. In addi-
tion, patients are exposed to potential complications resulting
from central venous access. Therefore, the simplified FOL-
FOX4 regimen is likely to have important implications for
the patient’s quality of life.
One of the major toxicities related to 5-FU/LV is myelo-
suppression. Chemotherapy-induced severe neutropenia can
also result in treatment-related hospitalization or mortality,
thereby compromising the quality of life and increasing medi-
cal expenditure. In a previous study with the FOLFOX4 reg-
imen, grade 3/4 neutropenia and febrile neutropenia occurred
in 36.9% and 7% of the patients, respectively (13). However,
in the current study, grade 3/4 neutropenia was only observed
in 2 patients (4.7%) and febrile neutropenia only in one (2.3
%). Furthermore, all these cases improved after treatment
with G-CSF and empirical antibiotics. These results seemed
to be due to reduced dose of LV (30 mg/m2) compared to that
(200 mg/m2) of the original FOLFOX4 regimen. Another
major toxicity related to oxaliplatin is peripheral neuropathy.
In the present study, grade 1/2 neuropathy was observed in
25.6% of patients, and was effectively treated with conserva-
tive therapies. Of the other non-hematologic adverse effects,
grade 1/2 nausea occurred in 34.9% of patients, yet grade 3
nausea was only observed in 2.3% of patients. 
In conclusion, the outpatient-basis regimen of oxaliplatin
plus 5-FU/LV was found to be well-tolerated and effective in
patients with metastatic or recurrent colorectal cancer. Accord-
ingly, the current regimen can be regarded as an important
outpatient treatment option for advanced colorectal cancer.
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Fig. 2. Time to progression and overall survival.
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B
NCI-CTC, National Cancer Institute Common Toxicity Criteria version 3.0.
No. of patients (%)
123 4
NCI-CTC grade
Grade 
3-4 (%)
Hematologic toxicity
Neutropenia  - 4 (9.3) 1 (2.3) 1 (2.3) 2 (4.7)
Anemia 1 (2.3) 10 (23.3) 2 (4.7) - 2 (4.7)
Thrombocytopenia  1 (2.3) 2 (11.6) 2 (4.7) 1 (2.3) 3 (7.0)
Non-hematologic toxicity
Nausea 7 (16.3) 8 (18.6) 1 (2.3) - 1 (2.3)
Diarrhea 3 (7.0) 1 (2.3) 1 (2.3) - 1 (2.3)
Febrile neutropenia - - 1 (2.3) - 1 (2.3)
Neuropathy 8 (18.6) 3 (7.0) - - 0 (0)
Table 3. Chemotherapy-related toxicities404 J.H. Moon, J.G. Kim, S.K. Sohn, et al.
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